Roth Capital Predicts Increased Earnings for InfuSystem

Key Points

• Roth Capital has raised its FY2025 EPS estimate for InfuSystem to $0.21, significantly up from a previous forecast of $0.13, maintaining a "Strong-Buy" rating on the stock.
• The current consensus estimate for InfuSystem's full-year earnings stands at $0.15 per share, indicating potential growth exceeding market expectations.
• Institutional ownership in InfuSystem remains strong, with hedge funds and institutional investors holding approximately 71.13% of the stock, reflecting investor confidence in the company's future performance.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Investment analysts at Roth Capital lifted their FY2025 EPS estimates for InfuSystem in a research report issued to clients and investors on Tuesday, August 5th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings per share of $0.21 for the year, up from their prior forecast of $0.13. Roth Capital has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share.

A number of other brokerages also recently issued reports on INFU. Wall Street Zen downgraded InfuSystem from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 14th. B. Riley upgraded InfuSystem to a "strong-buy" rating in a report on Thursday, May 8th.

InfuSystem Price Performance

Shares of InfuSystem stock opened at $8.01 on Friday. The stock has a market capitalization of $168.36 million, a P/E ratio of 134.86 and a beta of 1.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. The business's 50 day simple moving average is $6.04 and its two-hundred day simple moving average is $6.17. InfuSystem has a one year low of $4.61 and a one year high of $9.97.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in INFU. Minerva Advisors LLC increased its position in InfuSystem by 7.5% in the first quarter. Minerva Advisors LLC now owns 910,677 shares of the company's stock worth $4,899,000 after buying an additional 63,826 shares in the last quarter. Meros Investment Management LP raised its stake in InfuSystem by 2.6% during the 4th quarter. Meros Investment Management LP now owns 631,105 shares of the company's stock worth $5,333,000 after acquiring an additional 16,178 shares during the period. Dimensional Fund Advisors LP lifted its holdings in InfuSystem by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 456,043 shares of the company's stock valued at $3,853,000 after purchasing an additional 21,697 shares in the last quarter. Geode Capital Management LLC lifted its holdings in InfuSystem by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 444,476 shares of the company's stock valued at $3,756,000 after purchasing an additional 7,968 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of InfuSystem by 13.1% in the first quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company's stock worth $2,356,000 after purchasing an additional 50,877 shares in the last quarter. 71.13% of the stock is owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.